Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Atossa Therapeutics(ATOS) Newsfilter·2024-03-19 20:30(Z)-endoxifen的疗效 - Atossa Therapeutics, Inc.宣布一名乳腺癌患者在接受(Z)-endoxifen治疗五年后仍然没有癌症复发[1] - (Z)-endoxifen有望改变目前乳腺癌治疗范式，减少患者对目前标准治疗的不良反应[2] FDA批准 - FDA批准了一项单病例研究，允许该患者在手术前20天接受4mg/天的(Z)-endoxifen治疗[5] (Z)-endoxifen的特性 - (Z)-endoxifen是tamoxifen的最活跃代谢产物，具有抗雌激素效果，同时对PKCβ1具有靶向作用[12]